About Ademtech
Ademtech is a Healthcare company based in Pessac (France) founded in 2000. Superparamagnetic nanoparticles are manufactured for life sciences applications. It operates in the Healthcare, Technology, and Chemicals & Materials sectors. Its chief executive, as recorded, is Bernard Plichon. Ademtech offers products and services including Adembeads, Bio-Adembeads, Adem-Kit, and Streptavidin Coupling Service. Its focus areas include High Tech, Nanotechnology, Nanostructures and Metal and Metalloid. Its competitors include Ethypharm, GenOway and Mablink; 3 of its 3 listed competitors have raised funding.
Company details
Ademtech was founded in 2000 in Pessac, France, as a biotech company focused on superparamagnetic nanoparticles for life sciences. Calibrated particles of 100-500 nm, with about 70 iron oxides, are developed and produced with surface groups including amines, carboxylic acids, streptavidin, and antibodies. These are applied in genomics, proteomics, cell sorting, and molecular biology workflows that involve magnetic separation.
- Headquarters Pessac, France
- SectorsHealthcareTechnology Chemicals & Materials
- Email••••••••
- Website ademtech.com
- Social LinkedIn X Facebook
- Legal Name Ademtech
- Latest Funding Round$180K (USD), Grant
Nov 2010
- InvestorsGalia Gestion
& 1 more
Products & Services of Ademtech
Ademtech offers a comprehensive portfolio of products and services, including Adembeads, Bio-Adembeads, Adem-Kit, and Streptavidin Coupling Service.
Uniform particles for in vitro diagnostic applications.
Particles for molecular diagnostic and life sciences.
Kits for DNA extraction and amplification processes.
Service for coupling applications in diagnostics.
Funding Insights of Ademtech
- Total Rounds 2
- Last Round Grant — $180,000
- Investors Count 2
All 2 funding rounds of Ademtech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2010 | $180,000 | Grant | – | – | |
| Jun 2001 | Series A | – | – |
2 investors in total: 2 institutional.
Investors in Ademtech
Ademtech has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Galia Gestion and National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Galia Gestion is engaged in private equity investments in southwestern France. | galia-gestion.com | Bordeaux, France | ||
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States |
Investor details for Ademtech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ademtech
1 people are tracked at Ademtech (1 in leadership).
| Name | Role | Group |
|---|---|---|
Bernard Plichon | CEO | Leadership |
Complete people profiles for Ademtech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ademtech
3 dated milestones of Ademtech across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Ademtech is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $180K.
Competitors of Ademtech
Ademtech has 3 listed competitors in our database, 3 of them funded. They include Ethypharm, GenOway and Mablink.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ethypharm.com | 1977 | Saint Cloud, France | $248.09M | Therapies for pain and addiction treatment are developed. | ||
| genoway.com | 1999 | Lyon, France | $11.55M | Provider of transgenic rodent models and customized cell lines for preclinical development | ||
| mablink.com | 2018 | Lyon, France | $35M | Antibody-drug conjugate technology for cancer treatment is provided. |
Detailed competitors of Ademtech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ademtech
The website of Ademtech (ademtech.com) receives about 1K visits a month.
- Monthly visits1K
▼ 41.8% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Ademtech
Ademtech was founded in 2000 and raised its 1st funding round 1 year after it was founded.
Ademtech is headquartered in Pessac, France. It is registered at Pessac, Gironde, France.
Bernard Plichon is the CEO of Ademtech, as recorded in our data.
Ademtech was founded in 2000 in Pessac, France, as a biotech company focused on superparamagnetic nanoparticles for life sciences. Calibrated particles of 100-500 nm, with about 70 iron oxides, are developed and produced with surface groups including amines, carboxylic acids, streptavidin, and antibodies. These are applied in genomics, proteomics, cell sorting, and molecular biology workflows that involve magnetic separation.
Ademtech offers Adembeads, Bio-Adembeads, Adem-Kit, and Streptavidin Coupling Service.
Ademtech has 2 investors. Key investors include Galia Gestion, and National Science Foundation.
Ademtech operates through Ademtech.